FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4313236518> ?p ?o ?g. }

• W4313236518 endingPage "106" @default.
• W4313236518 startingPage "95" @default.
• W4313236518 abstract "Mobocertinib has demonstrated durable clinical benefit in platinum-pretreated patients (PPP) with epidermal growth factor receptor exon 20 insertion-positive non-small cell lung cancer (NSCLC).Pooled safety analysis of two studies included patients with NSCLC (N = 257) treated with the recommended phase 2 dose (RP2D) of mobocertinib (160 mg once daily). We report overall safety (treatment-emergent adverse events [TEAEs]) in the RP2D population; characterization of GI and skin-related events in 114 PPP from a phase 1/2 study (NCT02716116); and clinical activity in PPP with and without dose reductions due to TEAEs.In the RP2D population (N = 257), the most common TEAEs were diarrhea (93%), nausea (47%), rash (38%), and vomiting (37%). In PPP (N = 114), median times to diarrhea onset and resolution were 5 and 2 days, respectively. Median times to onset and resolution of skin-related events were 9 and 78 days, respectively. Among PPP with (n = 29) or without (n = 85) dose reductions due to TEAEs, overall response rates were 21% and 31% and median durations of response were 5.7 and 17.5 months, respectively.GI and skin-related events are common with mobocertinib; minimizing dose reductions with proactive management may improve clinical outcomes.NCT02716116; NCT03807778.Mobocertinib is a treatment for patients with a certain type of lung cancer. We analyzed the safety of mobocertinib in 257 patients with lung cancer. The most common side effects with mobocertinib were diarrhea, nausea, vomiting, and skin rash. In 114 patients with lung cancer who were treated in the past with chemotherapy that included platinum-based drugs, diarrhea started after about 5 days of mobocertinib treatment and went away in about 2 days. Skin-related side effects started after about 9 days and went away in about 2.5 months. One-fifth of patients who had to receive a smaller amount of mobocertinib because of side effects responded to treatment compared with one-third of patients who received the recommended mobocertinib amount. Managing side effects quickly can better help patients with lung cancer who are treated with mobocertinib." @default.
• W4313236518 created "2023-01-06" @default.
• W4313236518 creator A5006414890 @default.
• W4313236518 creator A5009262570 @default.
• W4313236518 creator A5019697239 @default.
• W4313236518 creator A5024628268 @default.
• W4313236518 creator A5035649087 @default.
• W4313236518 creator A5036466135 @default.
• W4313236518 creator A5044613951 @default.
• W4313236518 creator A5048675362 @default.
• W4313236518 creator A5054676638 @default.
• W4313236518 creator A5055074037 @default.
• W4313236518 creator A5056924605 @default.
• W4313236518 creator A5058521062 @default.
• W4313236518 creator A5060033755 @default.
• W4313236518 creator A5069070706 @default.
• W4313236518 creator A5076869363 @default.
• W4313236518 creator A5079966483 @default.
• W4313236518 creator A5085305552 @default.
• W4313236518 creator A5086209974 @default.
• W4313236518 creator A5088178599 @default.
• W4313236518 creator A5090068456 @default.
• W4313236518 creator A5090324173 @default.
• W4313236518 date "2022-12-28" @default.
• W4313236518 modified "2023-10-17" @default.
• W4313236518 title "Characterization and management of adverse events observed with mobocertinib (TAK-788) treatment for <i>EGFR</i> exon 20 insertion–positive non–small cell lung cancer" @default.
• W4313236518 cites W2016852257 @default.
• W4313236518 cites W2019607817 @default.
• W4313236518 cites W2057039211 @default.
• W4313236518 cites W2057145505 @default.
• W4313236518 cites W2075445339 @default.
• W4313236518 cites W2083220122 @default.
• W4313236518 cites W2104347254 @default.
• W4313236518 cites W2140980839 @default.
• W4313236518 cites W2143863753 @default.
• W4313236518 cites W2145173412 @default.
• W4313236518 cites W2151016309 @default.
• W4313236518 cites W2273212719 @default.
• W4313236518 cites W2425227520 @default.
• W4313236518 cites W2567564314 @default.
• W4313236518 cites W2609723037 @default.
• W4313236518 cites W2772666421 @default.
• W4313236518 cites W2773886054 @default.
• W4313236518 cites W2799334305 @default.
• W4313236518 cites W2838798742 @default.
• W4313236518 cites W2892284712 @default.
• W4313236518 cites W2914321117 @default.
• W4313236518 cites W2920175805 @default.
• W4313236518 cites W2953226611 @default.
• W4313236518 cites W2981389891 @default.
• W4313236518 cites W2995866033 @default.
• W4313236518 cites W3012479383 @default.
• W4313236518 cites W3030186186 @default.
• W4313236518 cites W3088045239 @default.
• W4313236518 cites W3114001070 @default.
• W4313236518 cites W3129535020 @default.
• W4313236518 cites W3132930574 @default.
• W4313236518 cites W3134706444 @default.
• W4313236518 cites W3169469275 @default.
• W4313236518 cites W3205918530 @default.
• W4313236518 cites W3206796634 @default.
• W4313236518 cites W4220669669 @default.
• W4313236518 cites W4224602524 @default.
• W4313236518 cites W4280651624 @default.
• W4313236518 doi "https://doi.org/10.1080/14737140.2023.2157815" @default.
• W4313236518 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36537204" @default.
• W4313236518 hasPublicationYear "2022" @default.
• W4313236518 type Work @default.
• W4313236518 citedByCount "1" @default.
• W4313236518 countsByYear W43132365182023 @default.
• W4313236518 crossrefType "journal-article" @default.
• W4313236518 hasAuthorship W4313236518A5006414890 @default.
• W4313236518 hasAuthorship W4313236518A5009262570 @default.
• W4313236518 hasAuthorship W4313236518A5019697239 @default.
• W4313236518 hasAuthorship W4313236518A5024628268 @default.
• W4313236518 hasAuthorship W4313236518A5035649087 @default.
• W4313236518 hasAuthorship W4313236518A5036466135 @default.
• W4313236518 hasAuthorship W4313236518A5044613951 @default.
• W4313236518 hasAuthorship W4313236518A5048675362 @default.
• W4313236518 hasAuthorship W4313236518A5054676638 @default.
• W4313236518 hasAuthorship W4313236518A5055074037 @default.
• W4313236518 hasAuthorship W4313236518A5056924605 @default.
• W4313236518 hasAuthorship W4313236518A5058521062 @default.
• W4313236518 hasAuthorship W4313236518A5060033755 @default.
• W4313236518 hasAuthorship W4313236518A5069070706 @default.
• W4313236518 hasAuthorship W4313236518A5076869363 @default.
• W4313236518 hasAuthorship W4313236518A5079966483 @default.
• W4313236518 hasAuthorship W4313236518A5085305552 @default.
• W4313236518 hasAuthorship W4313236518A5086209974 @default.
• W4313236518 hasAuthorship W4313236518A5088178599 @default.
• W4313236518 hasAuthorship W4313236518A5090068456 @default.
• W4313236518 hasAuthorship W4313236518A5090324173 @default.
• W4313236518 hasBestOaLocation W43132365181 @default.
• W4313236518 hasConcept C126322002 @default.
• W4313236518 hasConcept C143998085 @default.
• W4313236518 hasConcept C197934379 @default.
• W4313236518 hasConcept C2776256026 @default.
• W4313236518 hasConcept C2776694085 @default.

• next